Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trial

About the trial

Sponsor

Alliance for Clinical Trials in Oncology (with National Cancer Institute (NCI))

Tested

Genetic testing (other), Valemetostat Tosylate (drug), Magnetic Resonance Imaging (procedure), Computed Tomography (procedure), Bone scan (procedure), FDG-Positron Emission Tomography (procedure), PSMA PET Scan (procedure), Biospecimen Collection (procedure), Carboplatin (drug), Cabazitaxel (drug), Abiraterone Acetate (drug), Enzalutamide (drug), Lutetium Lu 177 Vipivotide Tetraxetan (drug)

Dates

Started 2025-02-06; completion 2034-10-11

Results posted

Not yet

This phase II trial evaluates whether genetic testing in prostate cancer is helpful in deciding which study treatment patients are assigned. Patient cancer tissue samples are obtained from a previous surgery or biopsy procedure and tested for deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) abnormalities or mutations in their cancer. Valemetostat tosylate is in a class of medications called EZH1/EZH2 inhibitors. It blocks proteins called EZH1 and EZH2, which may help slow or stop the spread of tumor cells. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cispl…

From ClinicalTrials.gov, last updated 2026-11-03. Full record, eligibility and contacts (opens in a new tab)

Industry funding

Caris Mpi, Inc. reported $9,100 in research payments for this study in 2025 (7 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.